Clinical pharmacodynamics of antifungals. (Q35623090)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

Clinical pharmacodynamics of antifungals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

author name string

David Andes

series ordinal

1

1 reference

9 August 2017

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

Infectious Disease Clinics of North America

17 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

635-649

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

17 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

The postantibiotic effect of antifungal agents against common pathogenic yeasts

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Animal model pharmacokinetics and pharmacodynamics: a critical review

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Influence of binding on the pharmacologic activity of antibiotics

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Antifungal susceptibility testing: practical aspects and current challenges

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Fluconazole-resistant candidosis in an HIV cohort.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Fluconazole-resistant Candida albicans

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Fluconazole-resistant Candida in AIDS patients. Report of two cases

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Evaluation of the E test for fluconazole susceptibility testing ofCandida albicans isolates from oropharyngeal candidiasis

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Clinical Evaluation and Microbiology of Oropharyngeal Infection Due to Fluconazole‐ResistantCandidain Human Immunodeficiency Virus–Infected Patients

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

1 reference

https://api.crossref.org/works/10.1016/S0891-5520(03)50063-1

7 January 2021

10.1016/S0891-5520(03)00063-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14711081 AND SRC:MED&resulttype=core&format=json

17 November 2019

1 reference